Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle

Journal of Bone and Mineral Research

Volumn 25, Issue 10, 2010, Pages 2184-2192

  Søe, Kent ^a   Delaissé, Jean Marie ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Collagen degradation; Glucocorticoid; Mineral; Osteoclast; Resorption cycle

Indexed keywords

COLLAGEN; PREDNISOLONE;

ARTICLE; BONE DEMINERALIZATION; BONE MINERAL; BONE STRUCTURE; CELL COUNT; CELL CYCLE; CELL ELONGATION; CELL MIGRATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEGATIVE FEEDBACK; OSTEOCLAST ACTIVITY; OSTEOLYSIS;

BONE RESORPTION; COLLAGEN; GLUCOCORTICOIDS; HUMANS; HYDROLYSIS; MICROSCOPY, ELECTRON, SCANNING; OSTEOCLASTS;

EID: 77957677941     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.113     Document Type: Article

References (47)

1. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319-1328.
2. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Dis. 2001;2:65-73.
3. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835-1841.
4. Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid- induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
5. Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89:4923-4928.
6. Dovio A, Perazzolo L, Saba L, et al. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol. 2006;154:745-751.
7. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-{kappa}B (NF-{kappa}B) ligand, osteoprotegerin, and receptor activator of NF-{kappa}B in mouse calvarial bones. Endocrinology. 2006;147:3613-3622.
8. Silverman SL, Lane NE. Glucocorticoid-induced osteoporosis. Curr Osteoporos Rep. 2009;7:23-26.
9. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;147:5592-5599.
10. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest. 2006;116:2152-2160.
11. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048.
12. Dempster DW, Moonga BS, Stein LS, Horbert WR, Antakly T. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J Endocrinol. 1997;154:397-406.
13. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res. 2005;20:390-398.
14. Tobias J, Chambers TJ. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones. Endocrinology. 1989;125:1290-1295.
15. Hirayama T, Sabokbar A, Athanasou NA. Effect of corticosteroids on human osteoclast formation and activity. J Endocrinol. 2002;175:155-163.
16. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674-1686. (Pubitemid 351847520)
17. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140:4382-4389. (Pubitemid 30666099)
18. Weinstein RS, Jilka RL, Michael Parfitt A, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282. (Pubitemid 28335186)
19. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 2005;65:9943-9952. (Pubitemid 41541475)
20. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res. 2002;17:979-986. (Pubitemid 34535135)
21. Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaissé JM. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leukemia Research. 2008;32:1661-1668.
22. Foged NT, Delaisse JM, Hou P, et al. Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay 1. J Bone Miner Res. 1996;11:226-237. (Pubitemid 26054180)
23. Goldstein J, Newbury D, Joy D, et al. Scanning Electron Microscopy and X-Ray Microanalysis. Kluwer Academic/Plenum Publishers, 2003.
24. Lakkakorpi PT, Vaananen HK. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res. 1991;6:817-826.
25. Saltel F, Destaing O, Bard F, Eichert D, Jurdic P. Apatite-mediated actin dynamics in resorbing osteoclasts. Mol Biol Cell. 2004;15:5231-5241.
26. Hollberg K, Nordahl J, Hultenby K, Mengarelli-Widholm S, Andersson G, Reinholt FP. Polarization and secretion of cathepsin K precede tartrate-resistant acid phosphatase secretion to the ruffled border area during the activation of matrix-resorbing clasts. J Bone Miner Metab. 2005;23:441-449.
27. Yumita S, Nicholson GC, Rowe DJ, Kent GN, Martin TJ. Biphasic effect of calcitonin on tartrate-resistant acid phosphatase activity in isolated rat osteoclasts. J Bone Miner Res. 1991;6:591-597.
28. Morko J, Kiviranta R, Mulari MTK, et al. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone. 2009;44:717-728.
29. Takahashi N, Ejiri S, Yanagisawa S, Ozawa H. Regulation of osteoclast polarization. Odontology. 2007;95:1-9.
30. Chambers TJ, Thomson BM, Fuller K. Effect of substrate composition on bone resorption by rabbit osteoclasts. J Cell Sci. 1984;70:61-71.
31. Stenbeck G, Horton MA. A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci. 2000;113:1577-1587.
32. Nordahl J, Hollberg K, Mengarelli-Widholm S, Andersson G, Reinholt FP. Morphological and functional features of clasts in low phosphate, vitamin D-deficiency rickets. Calcif Tissue Int. 2000;67:400-407.
33. Sato T, Foged NT, Delaisse JM. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res. 1998;13:59-66.
34. Everts V, Delaisse JM, Korper W, Beertsen W. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone 1. J Bone Miner Res. 1998;13:1420-1430.
35. Nakamura I, Takahashi N, Sasaki T, Jimi E, Kurokawa T, Suda T. Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. J Bone Miner Res. 1996;11:1873-1879.
36. Wijenayaka AK, Colby CB, Atkins GJ, Majewski P. Biomimetic hydroxyapatite coating on glass coverslips for the assay of osteoclast activity in vitro. J Mater Sci Mater Med. 2009;20:1467-1473.
37. Geblinger D, Geiger B, Addadi L. Surface-induced regulation of podosome organization and dynamics in cultured osteoclasts. Chembiochem. 2009;10:158-165.
38. Andersen TL, del Carmen OM, Kirkegaard T, Lenhard T, Foged NT, Delaisse JM. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone. 2004;35:1107-1119.
39. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473:201-209.
40. Jimi E, Nakamura I, Amano H, et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact [corrected and republished with original paging, article originally printed in Endocrinology 1996 May;137(5): 2187-90]. Endocrinology. 1996;137:2187-2190.
41. Mano H, Yuasa T, Kameda T, et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun. 1996;223:637-642.
42. Parikka V, Lehenkari P, Sassi ML, et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology. 2001;142:5371-5378.
43. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25:934-936.
44. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-899. (Pubitemid 41103445)
45. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16:97-103.
46. Vanderoost J, Søe K, Delaissé Jean-Marie, Lenthe GH. Direct effect of glucocorticoids on osteoclasts: simulation of mechanical consequences. J Biomechan. Abstract, in press.
47. Novack DV, Faccio R. Osteoclast motility: Putting the brakes on bone resorption. Ageing Res Rev. 2009; Published online November 27, 2009; DOI: 10.1016/j.arr.2009.09.005.